Summary of adverse events that occurred in three or more subjects overall*
| Adverse event | Emixustat 2.5 mg (N=7) n (%) | Emixustat 5 mg (N=9) n (%) | Emixustat 10 mg (N=7) n (%) | All subjects (N=23) n (%) |
| Any adverse event | 6 (85.7) | 8 (88.9) | 7 (100) | 21 (91.3) |
| Delayed dark adaptation | 1 (14.3) | 6 (66.7) | 4 (57.1) | 11 (47.8) |
| Erythropsia | 1 (14.3) | 3 (33.3) | 1 (14.3) | 5 (21.7) |
| Vision blurred | 2 (28.6) | 1 (11.1) | 1 (14.3) | 4 (17.4) |
| Photophobia | 1 (14.3) | 2 (22.2) | 0 | 3 (13.0) |
| Visual impairment | 1 (14.3) | 1 (11.1) | 1 (14.3) | 3 (13.0) |
*Percentages were based on the total number of subjects enrolled in each treatment group for the safety analysis set (N).